To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •History of impaired cardiac function or clinically significant cardiac disease (i.e. congestive heart failure (CHF) NYHA Class III or IV); myocardial infarction, unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy \< 6 months prior to study entry (beta blockers or digoxin are permitted) and LVEF \<40% (as measured at screening by MUGA or echocardiogram).
• •Patients with amylase or lipase greater than upper limit of normal range per local laboratory
• •History of pancreatitis
• •Uncontrolled hypertension defined as systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 90 mmHg, despite optimal medical management
• •Symptomatic metastatic brain or meningeal tumors unless the patient is \> 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry.
• •Patients with severe renal impairment or on dialysis
• •Known human immunodeficiency virus (HIV) infection or patients with an active hepatitis B or C infection necessitating treatment. Patients with chronic hepatitis B or C are eligible
• •Active clinically serious infections \> CTCAE Grade 2
• •Serious, non-healing wound, ulcer, or bone fracture
• •Known or suspected allergy or intolerance to any agent given in the course of this trial
• •Previous cancer that is distinct in primary site or histology from actual disease EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors \[Ta and Tis\] or any cancer curatively treated \> 3 years prior to study entry